# Rapamycin and Human Healthspan

Rapamycin has strong animal longevity evidence, but intermittent dosing has not yet established improved physical function in otherwise healthy older adults.

Preregistered primary-subclaim aggregation returns SC2Γ. Strong preclinical biology and selected exploratory human signals coexist with a directly relevant negative-direction functional primary null. Markers, body composition and other-indication clinical results do not identify sustained physical-function benefit for the registered regimen and population. This scores the stated positive proposition without a preset verdict or safety recommendation.

Dose, formulation, sex, exercise, baseline disease, species and endpoint boundaries were examined. No positive intermittent healthy-human physical-function effect is yet mapped across adults. Robust model lifespan/health effects retain their causal status in their actual contexts; translation uncertainty is not a downgrade of those observations.